| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2c4857603a8f3f04a22062d0a77adcf5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_de4657a4dc2fa2678e4e9e7f317432a2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f9b4b4c8e485b6d754cb9bd274ddba8e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-197
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-185
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4965
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-22 |
| filingDate |
2010-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4714b3e20adfee0a3e978fbc74e1bec7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_307afdf664b38ac5eeee8c0354499743 |
| publicationDate |
2012-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2012071027-A2 |
| titleOfInvention |
Nutraceutical based topical anxiolytic agent and method of use |
| abstract |
A nutraceutical-based anxiolytic agent (composition) for topical application is described. The formulation utilizes a combination of active ingredients directed to up-regulate the parasympathetic nervous system and calming vagal nerve enervation and its resultant stress symptomatology. The active ingredients in the topical composition include GABA (gamma-aminobutyric acid), L-theanine, Phenibut (beta-phenyl-gamma-aminobutyric acid), and casein tryptic hydrolysase. The active ingredients are dissolved in a lecithin organogel carrier such as Lipoderm or Phloderm to provide a superior transdermal delivery system. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104719918-A |
| priorityDate |
2009-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |